Lupus & antiphospholipid syndrome
Clinical characteristics and long-term outcomes in SLE–myositis overlap syndrome: a controlled retrospective cohort study
Authors' conclusion
SLE-myositis overlap syndrome represents a clinically important subgroup characterized by a predominance of non-Caucasian patients and a higher burden of extra-renal disease. The presence of myositis is an important prognostic marker associated with increased long-term mortality in patients with SLE.
Study context
- Population
- SLE patients followed between 1978 and 2024 in a single-centre cohort
- Participants
- 855 patients
- Exposure
- SLE-myositis overlap vs SLE without myositis
- SLE-myositis overlapn = 36
- SLE without myositisn = 819reference
- Outcome
- All-cause mortality
- Follow-up
- Median 22.4 years
Methodological detailssingle-centre, prospectively maintained cohort, Kaplan-Meier, multivariable Cox proportional hazards regression
- Single-centre
- Prospectively maintained cohort
- Kaplan-Meier
- Multivariable Cox proportional hazards regression
Main finding
As reported in the abstract
Log-rank P < 0.001
Observational data: associations, not effects.
Further findings
Afro-Caribbean ethnicity
P < 0.001
ILD
P < 0.001
Anti-RNP positivity
P < 0.001
Prevalence of myositis in the SLE cohort
- Myositis identified (36/855)
- 4.2%
Other independent predictors of mortality (multivariable Cox)
- Interstitial lung disease (ILD): HR 5.5, 95% CI 3.61-9.6; P = 0.004
- Malignancy: HR 3.1, 95% CI 2.9-11.6; P < 0.001
Original publication
Clinical characteristics and long-term outcomes in SLE–myositis overlap syndrome: a controlled retrospective cohort study. Rheumatology (Oxford). Published 31 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →